Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2024 16:25 ET | Source: Vigil Neuroscience, Inc.

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
February 29, 2024 16:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients’ barriers to genetic testing WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience,...
February 07, 2024 16:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
January 03, 2024 16:30 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected...
November 22, 2023 16:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
November 16, 2023 16:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent...
November 07, 2023 07:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small...
October 17, 2023 07:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease

WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
October 05, 2023 16:01 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
September 26, 2023 07:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...